Expanded leadership team positioned to advance the company’s development and commercialization plans NAARDEN, The Netherlands & WALTHAM, Mass. – Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the appointment of two key leaders to its management team – Mr. Rob Lauzen as Chief Financial … Continue reading Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer

OKLAHOMA CITY – CorriXR Therapeutics, Inc. (“CorriXR”), a biotherapeutics company developing unique genetic medicines that optimize the effectiveness of existing cancer treatments by knocking out genes responsible for resistance, today announced the appointment of Jill Castilla to its Board of Directors. Ms. Castilla brings visionary leadership as a nationally recognized innovator in finance and banking. “We are very pleased to welcome Jill to our Board … Continue reading CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors

Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality WATERTOWN, Mass. – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the function of beneficial proteins, today announced the appointment of Ruben Tommasi, Ph.D., as Chief Scientific Officer. Dr. Tommasi joins Entact with three … Continue reading Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer